Influence of a written or oral patient information program in daily clinical practice on adherence and persistence with an aromatase inhibitor in adjuvant primary breast cancer treatment in comparison to standard clinical care within outcome research. - The COMPAS-Study

Trial Profile

Influence of a written or oral patient information program in daily clinical practice on adherence and persistence with an aromatase inhibitor in adjuvant primary breast cancer treatment in comparison to standard clinical care within outcome research. - The COMPAS-Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Anastrozole (Primary) ; Tamoxifen
  • Indications Breast cancer; Early breast cancer
  • Focus Therapeutic Use
  • Acronyms COMPAS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 Sep 2013 COMPAS results published in BMC Cancer.
    • 22 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top